title: Beneficial effects of follistatin in hepatic ischemia-reperfusion injuries in rats.
abstract: BACKGROUND
  Ischemia-reperfusion injury has been demonstrated in a variety of clinical settings. The morbidity associated with liver transplantation and major hepatic resections is partly a result of ischemia-reperfusion injury. Follistatin, an activin-binding protein, binds to activins and subsequently blocks their action. It was reported that blockade of the action of activin with administration of follistatin accelerates recovery from ischemia renal injury. This study was conducted to investigate the involvement of the activin-follistatin system in hepatic ischemia-reperfusion injury.
  
  
  METHODS
  Total hepatic ischemia for 30 min was performed followed by reperfusion in a rat model. Rats were divided into two groups: a follistatin group and a control group. Follistatin (1 μg/body), which is an activin-binding protein, was administered at the time of reperfusion.
  
  
  RESULTS
  Though 80% of animals survived in the follistatin group, four of five animals died in the control group within 3 days after reperfusion (p<0.05). AST was significantly lower at 3 h after reperfusion in the follistatin group (p<0.05). LDH was also lower at 6 h after reperfusion in the follistatin group (p<0.05). Follistatin inhibited the mRNA expression of the βA subunit of activin. Moreover, the expression of IL-6, which is an inflammatory cytokine, was suppressed at 6 h after reperfusion in the follistatin group (p<0.05).
  
  
  CONCLUSIONS
  The present study demonstrated that treatment with follistatin reduced the expression of IL-6 and activin resulting in beneficial support for hepatic ischemia-reperfusion injuries.
authors.affiliation: Department of Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15, Kuramoto, Tokushima, 770-8503, Japan. kanamoto@clin.med.tokushima-u.ac.jp
authors.forename: Mami
authors.initials: M
authors.lastname: Kanamoto
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Shimada
authors.forename: Yuji
authors.initials: Y
authors.lastname: Morine
authors.forename: Tomoharu
authors.initials: T
authors.lastname: Yoshizumi
authors.forename: Satoru
authors.initials: S
authors.lastname: Imura
authors.forename: Toru
authors.initials: T
authors.lastname: Ikegami
authors.forename: Hiroki
authors.initials: H
authors.lastname: Mori
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Arakawa
mesh_terms: D028341:Activins / Q000096:biosynthesis; D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D038681:Follistatin / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000096:biosynthesis; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000293:injuries; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012038:Regeneration / Q000187:drug effects; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D038681:Follistatin; D015850:Interleukin-6; D028341:Activins; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase
references.citation: Placenta. 2000 Jan;21(1):38-43
references.pmid: 10692249
references.citation: J Neurochem. 2009 Dec;111(5):1138-48
references.pmid: 19780899
references.citation: Hepatology. 1996 Aug;24(2):361-6
references.pmid: 8690405
references.citation: Endocr J. 2006 Feb;53(1):73-8
references.pmid: 16543675
references.citation: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16239-44
references.pmid: 17911255
references.citation: Histol Histopathol. 1999 Jan;14(1):295-304
references.pmid: 9987674
references.citation: J Clin Invest. 1993 Sep;92(3):1491-6
references.pmid: 8376601
references.citation: J Hepatol. 1998 Dec;29(6):977-84
references.pmid: 9875645
references.citation: Brain Res. 2005 Aug 16;1053(1-2):1-9
references.pmid: 16038884
references.citation: Biochem Biophys Res Commun. 2007 Jun 29;358(2):500-5
references.pmid: 17490613
references.citation: Int J Cardiol. 2005 Apr 20;100(2):179-90
references.pmid: 15823623
references.citation: Mol Cell Endocrinol. 1999 Feb 25;148(1-2):129-36
references.pmid: 10221778
references.citation: Proc Soc Exp Biol Med. 1997 Jul;215(3):209-22
references.pmid: 9207855
references.citation: Hepatology. 2000 Apr;31(4):916-21
references.pmid: 10733548
references.citation: J Am Soc Nephrol. 2001 Aug;12(8):1685-1695
references.pmid: 11461941
references.citation: Transplant Proc. 1997 Feb-Mar;29(1-2):406-7
references.pmid: 9123057
references.citation: Exp Cell Res. 1996 Oct 10;228(1):106-13
references.pmid: 8892977
references.citation: J Endocrinol. 1999 May;161(2):195-8
references.pmid: 10320816
references.citation: Endocrinology. 2000 May;141(5):1905-8
references.pmid: 10803603
references.citation: Cardiovasc Res. 1992 Jul;26(7):656-9; discussion 600-1
references.pmid: 1423429
references.citation: Biochem Biophys Res Commun. 2005 Mar 25;328(4):937-43
references.pmid: 15707968